• metastatic/advanced RCC (mRCC) - 2nd line (L2) 1
• sarcomas
• thyroid cancer
• urothelial cancer (UC) - bladder cancer (BC)

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab alone
• atezolizumab plus SoC
• avelumab based treatment
• avelumab alone
• durvalumab based treatment
• durvalumab alone
• nivolumab based treatment
• nivolumab alone
• pembrolizumab based treatment
• pembrolizumab alone
• pembrolizumab plus SoC
• Immune checkpoint association
• durvalumab plus tremelimumab

• versus all
• vs chemotherapy
• vs platinum-based chemotherapy
• vs platinum derivate
• vs platinum association
• vs gemcitabine plus platin
• vs Standard of Care (SoC)
• vs placebo plus SoC
• vs non active control
• vs BSC
• vs no additional treatment
• vs placebo

  All patients Age < 65y (younger) Age > 65y Gender, female Gender, male Hemoglobin concentration < 10g/dl hemoglobin concentration > 10g/dl metastasis (liver ) metastasis (lymph node ) metastasis (visceral) PD-L1 < 1% PD-L1 < 10% PD-L1 > 1% PD-L1 > 10% smoker (Current) smoker (Former) smoker (never)

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)   studies

urothelial cancer (UC) - bladder cancer (BC), pembrolizumab alone vs. all, meta-analysis of study results

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;